Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Phase III study shows brentuximab improves progression-free survival in Hodgkin lymphoma

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) presents results from the phase III AETHERA trial, which evaluated the safety and efficacy of brentuximab vedotin in preventing post-autologous stem cell transplant disease recurrence in Hodgkin lymphoma patients.